8-K: Viatris Q2 Revenue Beats Estimates, Reaffirms 2025 Guidance

Viatris Inc. reported second quarter 2025 financial results with total revenues exceeding expectations and reiterated its full-year 2025 financial guidance.

Summary

• Total revenues for Q2 2025 were $3.58 billion, down 6% reported and 2% on a divestiture-adjusted operational basis compared to Q2 2024, but exceeded expectations.
• Excluding the negative Indore Impact, divestiture-adjusted operational total revenues increased 3% compared to Q2 2024.
• U.S. GAAP net loss for Q2 2025 was $(4.6) million, a significant improvement from $(326.4) million in Q2 2024.
• U.S. GAAP diluted EPS was $0.00 per share in Q2 2025, up from $(0.27) per share in Q2 2024.
• Adjusted EBITDA was $1.08 billion, down 11% reported and 4% divestiture-adjusted operational compared to Q2 2024.
• Adjusted EPS was $0.62 per share, down 10% reported and 4% divestiture-adjusted operational compared to Q2 2024.
• U.S. GAAP net cash provided by operating activities was $220 million, down 42% from Q2 2024.
• Free cash flow was $167 million, down 48% from Q2 2024.
• New product revenues generated approximately $79 million in Q2 2025.
• A goodwill impairment charge of $2.9 billion was recorded for the six months ended June 30, 2025.
• The company returned over $630 million of capital to shareholders year-to-date, including $350 million in share repurchases.
• Viatris reaffirmed its 2025 financial guidance, expecting total revenues between $13.5 billion and $14.0 billion, and adjusted EPS between $2.16 and $2.30.
• The company expects to be in the top half of the range for total revenues and adjusted EPS for 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While several key financial metrics showed year-over-year declines and a significant goodwill impairment was recorded, total revenues exceeded expectations, U.S. GAAP net loss improved substantially, and the company reaffirmed its full-year guidance, expecting to be in the top half of the range for key metrics. Positive pipeline developments and a strong commitment to shareholder returns also contribute to a positive outlook.

Positives

• Total revenues for Q2 2025 were above expectations.
• U.S. GAAP net loss significantly improved to $(4.6) million in Q2 2025 from $(326.4) million in Q2 2024.
• U.S. GAAP diluted EPS improved to $0.00 per share in Q2 2025 from $(0.27) per share in Q2 2024.
• Positive top-line results were announced for two pivotal Phase 3 trials: Phentolamine Ophthalmic Solution (MR-142) for night driving impairment and Phentolamine Ophthalmic Solution (MR-141) for presbyopia.
• The late-stage pipeline continues to advance with encouraging momentum, reinforced by five Phase 3 data readouts this year.
• The company returned more than $630 million of capital to shareholders year-to-date, including $350 million in share buybacks.
• Reiterated 2025 financial guidance ranges across all metrics, with an expectation to be in the top half of the range for Total Revenues and Adjusted EPS.
• Brands net sales showed strong performance in Greater China and Emerging Markets, and growth in certain key brands in Developed Markets.
• Continued growth was observed in Yupelri and Breyna in North America, with strong performance across key European markets and slight volume growth in JANZ for Generics.
• Received approval for INPEFA 200mg and 400mg film-coated tablets in United Arab Emirates in June 2025.
• Five abstracts from the Phase 3 program for Meloxicam (MR-107A-02) in acute surgical pain models will be presented at PAINWeek 2025, including positive results from two pivotal studies.

Negatives

• Total revenues decreased 6% on a reported basis and 2% on a divestiture-adjusted operational basis compared to Q2 2024.
• Total net sales decreased 6% on a reported basis and 2% on a divestiture-adjusted operational basis compared to Q2 2024.
• Adjusted EBITDA decreased 11% on a reported basis and 4% on a divestiture-adjusted operational basis compared to Q2 2024.
• Adjusted EPS decreased 10% on a reported basis and 4% on a divestiture-adjusted operational basis compared to Q2 2024.
• U.S. GAAP net cash provided by operating activities decreased 42% to $220 million in Q2 2025.
• Free cash flow decreased 48% to $167 million in Q2 2025.
• A goodwill impairment charge of $2.9 billion was recorded for the six months ended June 30, 2025.
• The Phase 3 study for Pimecrolimus Ophthalmic Ointment (MR-139) for blepharitis did not meet its primary endpoint.
• Generics net sales reflect the expected negative Indore Impact and competition on Wixela.

Risks

• The estimated negative financial impact on 2025 total revenues and earnings from operations due to the FDA warning letter and import alert related to the Indore, India manufacturing facility, with an estimated impact to total revenues of approximately $160 million for Q2 2025 and $300 million for the six months ended June 30, 2025.
• The Phase 3 program for Pimecrolimus Ophthalmic Ointment (MR-139) did not meet its primary endpoint, leading to an evaluation of appropriate next steps.
• Competition on products such as Wixela is negatively impacting Generics net sales.

Future Outlook

Viatris reaffirmed its 2025 financial guidance across all metrics and expects to achieve results in the top half of the range for Total Revenues and Adjusted EPS. The company remains focused on driving commercial execution, investing in strategic accretive in-market business development opportunities, and positioning for sustainable growth in 2026 and beyond. It also expects to continue opportunistic share repurchases, targeting $500 million to $650 million in total for 2025, and to pursue regional licensing and partnership opportunities that leverage its commercial and R&D infrastructure.

Management Comments

• Scott A. Smith, CEO: "We delivered a strong second quarter and continued to make meaningful progress against our key 2025 strategic priorities. We believe our results reflect the strength and resilience of our diversified global business, and our late-stage pipeline continues to advance with encouraging momentum. We are progressing our enterprise-wide strategic review and continue to return significant capital to shareholders. We remain focused on driving commercial execution, investing in strategic accretive in-market business development opportunities and positioning Viatris for sustainable growth in 2026 and beyond."
• Doretta Mistras, CFO: "Our second-quarter results exceeded our expectations, and we continue to execute with financial discipline—delivering strong operational performance, reaffirming all key elements of our 2025 financial guidance ranges and building momentum into the second half of the year. With more than $630 million in capital returned to shareholders year-to-date and visibility into continued growth across key regions, we remain confident in our ability to deliver on our financial commitments."

Industry Context

Viatris operates as a global healthcare company aiming to bridge the divide between generics and brands, providing access to high-quality medicines worldwide. The company's diversified global business and advancing late-stage pipeline are key elements of its strategy within the competitive pharmaceutical industry.

Related Party Transactions

• Adjustments to financial measures include reclassifications related to TSA reimbursements primarily from the contribution of the biosimilars business to Biocon Biologics Limited in November 2022.

Stakeholder Impact

• Shareholders: Impacted by financial performance, capital returns through share repurchases, and future guidance.
• Customers: Benefit from continued access to high-quality medicines and potential new product launches from the pipeline.
• Employees: Potential impact from restructuring activities, though no direct employee-specific details were provided.
• Suppliers: Potential impact from supply chain risks mentioned in forward-looking statements, but no direct details were provided.

Next Steps

• Host a conference call and live webcast on August 7, 2025, to review financial results.
• Evaluate appropriate next steps for the Pimecrolimus Ophthalmic Ointment (MR-139) Phase 3 program.
• Present five abstracts from the Meloxicam (MR-107A-02) Phase 3 program at PAINWeek 2025 from September 2-5, 2025.
• Continue progressing the enterprise-wide strategic review.
• Remain focused on driving commercial execution.
• Invest in strategic accretive in-market business development opportunities.
• Position Viatris for sustainable growth in 2026 and beyond.
• Continue opportunistic share repurchases, expecting $500 million to $650 million in total for 2025.
• Pursue regional licensing and partnership opportunities with immediate revenue contribution.

Key Dates

Recommendation

Viatris's Q2 2025 results present a mixed picture. While total revenues exceeded expectations and U.S. GAAP net loss significantly improved, key adjusted metrics like EBITDA and EPS, along with cash flow, saw year-over-year declines. The substantial goodwill impairment charge is a notable concern. However, the company's reaffirmation of its full-year 2025 guidance, with an expectation to hit the top half of the range for revenues and adjusted EPS, coupled with positive late-stage pipeline developments and a strong commitment to returning capital to shareholders, suggests underlying strategic progress. Given these offsetting factors, a 'hold' recommendation is appropriate, advising investors to monitor the execution of strategic initiatives and the impact of the Indore facility issues on future performance.

Keywords

Viatris, VTRS, Pharmaceuticals, Healthcare, Q2 2025 Earnings, Financial Results, Guidance, Pipeline, Capital Allocation, Generics, Brands